🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

WNL Op Zondag Academie: Met hoogleraar Marcel Levi (NWO) bespreken we wetenschappelijk nieuws. En met dr Myriam Chalabi die onderzoek doet naar een succesvolle vorm van immunotherapie. Kijk WNL Op Zondag, 10 uur, NPO1 #wnl Marcel levi Myriam Chalabi

Excited to present 🎤 first data #SABCS24 from TONIC2. Follow-up from nature.com/articles/s4159…. Are immune induction with dox or cisplatin indeed benefiting pts? Veerle Geurts at P1-7-30 and new data on acquired resist🔬 to aPD1 at PS17-09 The Netherlands Cancer Institute OncoAlert Nature Medicine

Meet the women on X changing the face of oncology. These peer-nominated oncologists are not just socially influential but deeply inspiring. Let’s celebrate their brilliance! #LARVOL #CancerResearch #Oncology #OncologyInsights #OncologyUpdates #CancerCare #CancerData

Meet the 2024 Top Oncologists on X for Gastrointestinal (GI) Cancer! Ranked based on peer nomination and influence on social media, these oncology leaders are advancing the fight against GI cancer. #LARVOL #GICancer #CancerResearch #Oncology #OncologyInsights #CancerData

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy. Read the full CheckMate 8HW trial results: nej.md/4eGp1tj #oncology

The Top GI Cancer Trials for 2024 are here! Curated by LARVOL CLIN with insights from 5,000 oncologists on X #LARVOL #Oncology #GICancer #CancerResearch #OncologyUpdates #CancerData #ClinicalTrials

END OF YEAR TOP ALL CANCER TRIALS in 2024! JUST in on 1 JAN 2025: Paper 1: #neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma ASCO

Paper 6: #ChalabiPlot (aka Myriam Chalabi) strikes again! Results from the NICHE-2 trial initially presented ESMO - Eur. Oncology 2022 now NEJM: near 100% pathologic response with neoadjuvant nivo/ipi in dMMR colon cancer nejm.org/doi/full/10.10…

My group is expanding! Position available for a PhD student in computational biology/bioinformatics to work on a goldmine of data from neoadj IO trials using the newest techniques! Click below for more info. nki.nl/careers-study/…

Long awaited practice-changing results from ph 3 CM8HW now out in The Lancet. Nivo/ipi sign better than nivo mono in dMMR mCRC Sara Lonardi Bristol Myers Squibb #GI25 thelancet.com/journals/lance…

Was initially skeptical of IO+RT for MSS rectal cancer, but do think there’s something there. Challenge is to optimize dose/timing/target volume, & patient selection. Tarzan study by Myriam Chalabi used short course RT+atezo/bev resulting in 42% organ preservation at 2 years.

Honoring the tireless efforts of oncologists on the front lines of cancer research and care.  This month, we're celebrating their achievements with a billboard in the heart of Times Square.  Thank you for your unwavering commitment!   #LARVOL #Oncology #TimesSquare #CancerCare

Wow🤩honored to be amongst outstanding oncologists on a TIMES SQUARE billboard! Wish I could’ve seen it live. Thank you LARVOL ONCO BRUNO for highlighting and celebrating dedication. Note: so many excellent peers not shown here/not on X 👏 👏 👏 👏The Netherlands Cancer Institute

Today is #WorldCancerDay 👉Interview with ESMO - Eur. Oncology Lifetime Achievement Award winner John Haanen of LUMC Leiden & The Netherlands Cancer Institute: 'Building a hopeful future for #oncology: using people’s own cells in the fight against #cancer' 🔗wp.me/panTdn-42X Maria Bolevich 📚🌍📰🐕🌊 European Parliamentary Research Service

Happy to see positive results with chemo + neoandjuvant IO (without the adjuvant!), even as a non-lung specialist! First #NADINA The Netherlands Cancer Institute in #melanoma, now #NSCLC! Curious to see the data! Hoping to see more de-escalation trials, goe more efficient and as effective treatments!

📣#ESMO25: 🔬 Your opportunity for global impact. Submit your abstract and share your findings with the world’s leading oncology experts. ⏰ Abstract deadline 13 May 2025 🔗ow.ly/fp2f50VusBO

Beautiful review on neoadjuvant immunotherapy across tumor types & how we can further refine delivery and develop biomarkers Nature Cancer. Congratulations to Drs. Gil Awada, Tina Cascone, Michiel van der Heijden Christian Blank MarleenKokLab Myriam Chalabi nature.com/articles/s4301…

Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NSCLC, TNBC, GI + bladder cancers, melanoma and many more: written with close friends and KOLs published today in Nature Cancer MarleenKokLab doi.org/10.1038/s43018…